Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers

European Neuropsychopharmacology

Volumn 27, Issue 2, 2017, Pages 192-203

  Waller, Jessica A ^a   Tamm, Joseph A ^a   Abdourahman, Aicha ^a   Pehrson, Alan L ^a   Li, Yan ^a   Cajina, Manuel ^a   Sánchez, Connie ^a  

^a LUNDBECK RESEARCH USA   (United States)

Author keywords

Immediate early gene; Multimodal; Neurodevelopment; Neuroplasticity; Transcription regulation

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; ESTROGEN RECEPTOR ALPHA; FLUOXETINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; PROTEIN FOS; SEMAPHORIN; SEMAPHORIN 4G; UNCLASSIFIED DRUG; VORTIOXETINE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; PIPERAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SULFIDE;

ADULT; AMYGDALA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EX VIVO STUDY; FRONTAL CORTEX; HIPPOCAMPUS; IMMEDIATE EARLY GENE; LONG TERM EXPOSURE; MALE; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; TRANSCRIPTION REGULATION; ANIMAL; BLOOD; DRUG EFFECTS; FRONTAL LOBE; GENE EXPRESSION; METABOLISM; SPRAGUE DAWLEY RAT;

AMYGDALA; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOMARKERS; FLUOXETINE; FRONTAL LOBE; GENE EXPRESSION; HIPPOCAMPUS; MALE; PIPERAZINES; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS; SULFIDES;

EID: 85009784259     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.11.014     Document Type: Article

References (42)

1. Andrade, C., Rao, N.S., How antidepressant drugs act: a primer on neuroplasticity as the eventual mediator of antidepressant efficacy. Indian J. Psychiatry 52 (2010), 378–386.
2. Bang-Andersen, B., Ruhland, T., Jorgensen, M., Smith, G., Frederiksen, K., Jensen, K.G., Zhong, H., Nielsen, S.M., Hogg, S., Mork, A., Stensbol, T.B., Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem. 54 (2011), 3206–3221.
3. Basar, E., Basar-Eroglu, C., Karakas, S., Schurmann, M., Brain oscillations in perception and memory. Int. J. Psychophysiol. 35 (2000), 95–124.
4. Bouzioukh, F., Daoudal, G., Falk, J., Debanne, D., Rougon, G., Castellani, V., Semaphorin3A regulates synaptic function of differentiated hippocampal neurons. Eur. J. Neurosci. 23 (2006), 2247–2254.
5. Bramham, C.R., Alme, M.N., Bittins, M., Kuipers, S.D., Nair, R.R., Pai, B., Panja, D., Schubert, M., Soule, J., Tiron, A., Wibrand, K., The Arc of synaptic memory. Exp. Brain Res 200 (2010), 125–140.
6. Burkhardt, C., Muller, M., Badde, A., Garner, C.C., Gundelfinger, E.D., Puschel, A.W., Semaphorin 4B interacts with the post-synaptic density protein PSD-95/SAP90 and is recruited to synapses through a C-terminal PDZ-binding motif. FEBS Lett. 579 (2005), 3821–3828.
7. Castren, E., Hen, R., Neuronal plasticity and antidepressant actions. Trends Neurosci. 36 (2013), 259–267.
8. Chen, F., du Jardin, K.G., Waller, J.A., Sanchez, C., Nyengaard, J.R., Wegener, G., Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus. Eur. Neuropsychopharmacol. 26 (2015), 234–245.
9. Dale, E., Zhang, H., Leiser, S.C., Xiao, Y., Lu, D., Yang, C.R., Plath, N., Sanchez, C., Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol. 28 (2014), 891–902.
10. du Jardin, K.G., Jensen, J.B., Sanchez, C., Pehrson, A.L., Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur. Neuropsychopharmacol. 24 (2014), 160–171.
11. du Jardin KG, S.C., Wegener, G., Elfving, B., Single dose vortioxetine or ketamine but not fluoxetine increases expression of neuroplasticity genes in the rat prefrontal cortex. Eur. Neuropsychopharmacol., 23, 2013, S392.
12. Duman, R.S., Depression: a case of neuronal life and death?. Biol. Psychiatry 56 (2004), 140–145.
13. Fleischmann, A., Hvalby, O., Jensen, V., Strekalova, T., Zacher, C., Layer, L.E., Kvello, A., Reschke, M., Spanagel, R., Sprengel, R., Wagner, E.F., Gass, P., Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J. Neurosci. 23 (2003), 9116–9122.
14. Guilloux, J.P., Mendez-David, I., Pehrson, A., Guiard, B.P., Reperant, C., Orvoen, S., Gardier, A.M., Hen, R., Ebert, B., Miller, S., Sanchez, C., David, D.J., Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 73 (2013), 147–159.
15. Hamilton, J.P., Siemer, M., Gotlib, I.H., Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Mol. Psychiatry 13 (2008), 993–1000.
16. Jain, N., Zhang, T., Fong, S.L., Lim, C.P., Cao, X., Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene 17 (1998), 3157–3167.
17. Jensen, J.B., du Jardin, K.G., Song, D., Budac, D., Smagin, G., Sanchez, C., Pehrson, A.L., Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur. Neuropsychopharmacol. 24 (2014), 148–159.
18. Kaiser, J., Lutzenberger, W., Human gamma-band activity: a window to cognitive processing. Neuroreport 16 (2005), 207–211.
19. Katona, C., Hansen, T., Olsen, C.K., A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 27 (2012), 215–223.
20. Knapska, E., Kaczmarek, L., A gene for neuronal plasticity in the mammalian brain: zif268/egr-1/ngfi-a/krox-24/tis8/zenk?. Prog. Neurobiol. 74 (2004), 183–211.
21. Koenigs, M., Grafman, J., The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav. Brain Res 201 (2009), 239–243.
22. Kollack-Walker, S., Don, C., Watson, S.J., Akil, H., Differential expression of c-fos mRNA within neurocircuits of male hamsters exposed to acute or chronic defeat. J. Neuroendocrinol. 11 (1999), 547–559.
23. Krishnan, V., Nestler, E.J., Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 167 (2010), 1305–1320.
24. Leiser, S.C., Pehrson, A.L., Robichaud, P.J., Sanchez, C., Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine – a quantitative EEG study in rats. Br. J. Pharmacol. 171 (2014), 4255–4272.
25. Li, Y., Abdourahman, A., Tamm, J.A., Pehrson, A.L., Sanchez, C., Gulinello, M., Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice. Pharmacol. Biochem. Behav. 135 (2015), 70–82.
26. Li, Y., Pehrson, A.L., Waller, J.A., Dale, E., Sanchez, C., Gulinello, M., A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)׳s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression. Front. Neurosci., 9, 2015, 279.
27. Mahableshwarkar, A.R., Zajecka, J., Jacobson, W., Chen, Y., Keefe, R.S., A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40 (2015), 2025–2037.
28. Mao, L.M., Wang, J.Q., Synaptically localized mitogen-activated protein kinases: local substrates and regulation. Mol. Neurobiol., 2015.
29. McIntyre, R.S., Lophaven, S., Olsen, C.K., A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 17 (2014), 1557–1567.
30. Mork, A., Montezinho, L.P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., Gulinello, M., Sanchez, C., Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol. Biochem. Behav. 105 (2013), 41–50.
31. Pehrson, A.L., Sanchez, C., Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 19 (2014), 121–133.
32. Pehrson, A.L., Leiser, S.C., Gulinello, M., Dale, E., Li, Y., Waller, J.A., Sanchez, C., Treatment of cognitive dysfunction in major depressive disorder—a review of the evidence for the efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and the multimodal-acting antidepressant vortioxetine. Eur. J. Pharmacol. 753 (2015), 19–31.
33. Riga MS, C.P., Sanchez, C., Artigas, F., Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine. Eur. Neuropsychopharmacol. 23 (2013), S393–S394.
34. Russo, S.J., Nestler, E.J., The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14 (2013), 609–625.
35. Sanchez, C., Asin, K.E., Artigas, F., Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol. Ther. 145 (2015), 43–57.
36. Sapolsky, R.M., Depression, antidepressants, and the shrinking hippocampus. Proc. Natl. Acad. Sci. USA 98 (2001), 12320–12322.
37. Sarvari, M., Hrabovszky, E., Kallo, I., Solymosi, N., Toth, K., Liko, I., Szeles, J., Maho, S., Molnar, B., Liposits, Z., Estrogens regulate neuroinflammatory genes via estrogen receptors alpha and beta in the frontal cortex of middle-aged female rats. J. Neuroinflammation, 8, 2011, 82.
38. Wallace, A., Pehrson, A.L., Sanchez, C., Morilak, D.A., Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int. J. Neuropsychopharmacol. 17 (2014), 1695–1706.
39. Waller, J.A., Chen, F., Sanchez, C., Vortioxetine promotes maturation of dendritic spines in vitro: a comparative study in hippocampal cultures. Neuropharmacology 103 (2016), 143–154.
40. 42 Waller, J.A., Nygaard, S.H., Li, Y., du Jardin, K.G., Tamm, J.A., Abdourahman, A., Elfving, B., Pehrson, A.L., Sanchez, C., Wernersson, R., 2016. Network analysis of neuroplasticity pathways modulated by vortioxetine in rodents -a bioinformatics approach (submitted for publication).
41. Ward, L.M., Synchronous neural oscillations and cognitive processes. Trends Cogn. Sci. 7 (2003), 553–559.
42. Yang, T.T., Simmons, A.N., Matthews, S.C., Tapert, S.F., Frank, G.K., Max, J.E., Bischoff-Grethe, A., Lansing, A.E., Brown, G., Strigo, I.A., Wu, J., Paulus, M.P., Adolescents with major depression demonstrate increased amygdala activation. J Am. Acad. Child Adolesc. Psychiatry 49 (2010), 42–51.